Saraju Dalsania, MD
Internal Medicine · Statesboro, GANPI 1346420494
Payments from drug & device makers
Across 211 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$686
- AbbVie$487
- Medtronic$439
- Pfizer$399
- Amgen$273
- Bayer$271
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,17897%
- Education$1323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $686 |
| AbbVie(2 entities) | 24 | $487 |
| Medtronic(2 entities) | 10 | $439 |
| Pfizer | 23 | $399 |
| Amgen | 8 | $273 |
| Bayer | 7 | $271 |
| Otsuka America Pharmaceutical, Inc. | 2 | $250 |
| Amarin Pharma, Inc. | 9 | $181 |
| Astellas Pharma US Inc | 3 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Xeris Pharmaceuticals, Inc. | 6 | $104 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| Esperion Therapeutics, Inc. | 6 | $92 |
| Novartis | 5 | $91 |
| IBSA Pharma Inc. | 4 | $79 |
| AstraZeneca | 4 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Lilly USA, LLC | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Lundbeck LLC | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Radius Health, Inc. | 1 | $26 |
| Insulet Corporation | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Vital Connect, Inc | 1 | $18 |
| Corcept Therapeutics | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$291
- REXULTI$250
- Kerendia$125
- VRAYLAR$125
- KRYSTEXXA$124
How this compares
$4,310 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $198,321 |
| RybelsusSemaglutide | 82 | $148,043 |
| EliquisApixaban | 66 | $69,632 |
| MounjaroTirzepatide | 43 | $50,871 |
| Tresiba Flextouch U-100Insulin Degludec | 88 | $43,854 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $38,151 |
| FarxigaDapagliflozin Propanediol | 34 | $36,813 |
| TradjentaLinagliptin | 32 | $33,544 |
| JanuviaSitagliptin Phosphate | 23 | $27,678 |
| MyrbetriqMirabegron | 22 | $24,295 |
| JardianceEmpagliflozin | 22 | $22,614 |
| XareltoRivaroxaban | 15 | $21,422 |
| TrulicityDulaglutide | 16 | $15,243 |
| Humulin R U-500Insulin Regular, Human | 11 | $14,726 |
| GemtesaVibegron | 14 | $13,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $686 | $346,364251 claims |
| PfizerEliquis, Abrysvo | $399 | $82,177108 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25 | $47 | $69,77974 claims |
| AstraZenecaFarxiga | $76 | $36,81334 claims |
| Astellas Pharma US IncMyrbetriq | $138 | $24,29522 claims |
| Johnson & JohnsonXarelto | $26 | $21,42215 claims |
| AbbVieSynthroid, Savella | $487 | $15,947130 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $59 | $10,18515 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $39 | $9,29514 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $26 | $7,25424 claims |
| Sanofi-aventis U.S. LLCLantus | $96 | $4,60622 claims |
| Esperion Therapeutics, Inc.Nexletol | $92 | $4,22011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Statesboro
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.